BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26259502)

  • 1. Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience.
    Chakupurakal G; Leitzke S; Langerbeins P; Schiller J; Schneider PM; Holtick U; Shimabukuro-Vornhagen A; Theurich S; Chemnitz J; Hallek M; von Bergwelt-Baildon M; Scheid C
    Ann Hematol; 2015 Oct; 94(10):1717-25. PubMed ID: 26259502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
    J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
    Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
    Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving role of stem cell transplantation in chronic lymphocytic leukemia.
    Dreger P;
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):355-69. PubMed ID: 23561478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis.
    Dreger P; Brand R; Milligan D; Corradini P; Finke J; Lambertenghi Deliliers G; Martino R; Russell N; van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2005 Jun; 19(6):1029-33. PubMed ID: 15830011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.
    Algrin C; Golmard JL; Michallet M; Reman O; Huynh A; Perrot A; Sirvent A; Plesa A; Salaun V; Béné MC; Bories D; Tournilhac O; Merle-Béral H; Leblond V; Le Garff-Tavernier M; Dhedin N
    Eur J Haematol; 2017 Apr; 98(4):363-370. PubMed ID: 27943415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
    Pavletic ZS; Arrowsmith ER; Bierman PJ; Goodman SA; Vose JM; Tarantolo SR; Stein RS; Bociek G; Greer JP; Wu CD; Kollath JP; Weisenburger DD; Kessinger A; Wolff SN; Armitage JO; Bishop MR
    Bone Marrow Transplant; 2000 Apr; 25(7):717-22. PubMed ID: 10745256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective.
    Dreger P; Michallet M; Schmitz N
    Ann Oncol; 2000; 11 Suppl 1():49-53. PubMed ID: 10707779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort.
    Toze CL; Dalal CB; Nevill TJ; Gillan TL; Abou Mourad YR; Barnett MJ; Broady RC; Forrest DL; Hogge DE; Nantel SH; Power MM; Song KW; Sutherland HJ; Smith CA; Narayanan S; Young SS; Connors JM; Shepherd JD
    Br J Haematol; 2012 Jul; 158(2):174-185. PubMed ID: 22640008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
    Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
    J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
    Krejci M; Doubek M; Brychtova Y; Stehlikova O; Chovancova J; Tichy B; Francova HS; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
    Ann Hematol; 2013 Jan; 92(2):249-54. PubMed ID: 23014659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis.
    Válková V; Schwarz J; Vítek A; Marková M; Pohlreich D; Benešová K; Michalová K; Cetkovský P; Trněný M
    Hematol Oncol; 2011 Mar; 29(1):22-30. PubMed ID: 20535783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia.
    Jaglowski SM; Byrd JC
    Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S132-8. PubMed ID: 22226097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Allogeneic transplantation in malignant lymphoma].
    Stötzer OJ; Schleuning M; Ledderose G; Hiddemann W; Kolb HJ
    Dtsch Med Wochenschr; 2001 Sep; 126(39):1062-9. PubMed ID: 11602913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia.
    Dreger P; Montserrat E
    Leukemia; 2002 Jun; 16(6):985-92. PubMed ID: 12040430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.